M.D.C. (MDC) Price Target Increased to $32.00 by Analysts at UBS Group
M.D.C. (NYSE:MDC) had its price target upped by equities researchers at UBS Group from $30.00 to $32.00 in a report released on Wednesday, 99wallstreet.com reports. The brokerage currently has a “sell” rating on the construction company’s stock. UBS Group’s target price would suggest a potential downside of 4.88% from the company’s previous close.
Several other equities analysts also recently commented on the company. Citigroup lowered their price target on M.D.C. from $37.00 to $34.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. ValuEngine downgraded M.D.C. from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 2nd. Zacks Investment Research upgraded M.D.C. from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, KeyCorp reissued a “hold” rating on shares of M.D.C. in a research report on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $30.33.
Shares of M.D.C. (NYSE MDC) traded down $0.48 during mid-day trading on Wednesday, reaching $33.64. The company’s stock had a trading volume of 416,700 shares, compared to its average volume of 533,700. M.D.C. has a one year low of $25.87 and a one year high of $37.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.60 and a current ratio of 9.45. The firm has a market capitalization of $1,910.00, a P/E ratio of 12.10, a PEG ratio of 0.88 and a beta of 1.38.
In other news, Director Herbert T. Buchwald sold 28,350 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $31.52, for a total value of $893,592.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director David Siegel sold 2,500 shares of the stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $31.83, for a total value of $79,575.00. The disclosure for this sale can be found here. 25.30% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. Amalgamated Bank bought a new position in M.D.C. in the second quarter worth $202,000. Capital Fund Management S.A. bought a new position in M.D.C. in the second quarter worth $223,000. Sawgrass Asset Management LLC bought a new position in M.D.C. in the third quarter worth $262,000. Parametrica Management Ltd bought a new position in M.D.C. in the third quarter worth $285,000. Finally, Piedmont Investment Advisors LLC bought a new position in M.D.C. in the second quarter worth $315,000. 74.15% of the stock is owned by hedge funds and other institutional investors.
M.DC Holdings, Inc is engaged in two primary operations, including homebuilding and financial services. The Company’s segments include West, including segments located in Arizona, California, Nevada and Washington; Mountain, including segments located in Colorado and Utah; East, including segments located in Virginia, Florida and Maryland, which includes Pennsylvania and New Jersey; mortgage operations, including HomeAmerican Mortgage Corporation, and Other, which includes Allegiant Insurance Company, Inc, StarAmerican Insurance Ltd., American Home Insurance Agency, Inc and American Home Title and Escrow Company.
Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.